Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DI-Leu16-IL2 in B-cell Non-Hodgkin Lymphoma
NCT01874288Phase 2Terminated
- Sponsor
- Alopexx Oncology, LLC
- Start
- Nov 2013
- Primary completion
- Jan 2014
- Modality
- Cytokines & Interferons, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of DI-Leu16-IL2 in B-cell non-Hodgkin lymphoma, sponsored by Alopexx Oncology, LLC. Started Nov 2013; status: terminated.
02
Drugs
DI-Leu16-IL2
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT01874288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01874288.